<DOC>
	<DOCNO>NCT01571453</DOCNO>
	<brief_summary>This study conduct aim investigate efficacy , safety tolerability 10 mg/day Vortioxetine Asian patient compare approve active comparator ( venlafaxine extend release 150 mg/day ) .</brief_summary>
	<brief_title>Study Vortioxetine ( Lu AA21004 ) Major Depressive Disorder Asian Countries</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Venlafaxine Hydrochloride</mesh_term>
	<mesh_term>Vortioxetine</mesh_term>
	<criteria>The patient suffers recurrent MDD primary diagnosis accord DSMIVTR™ criterion . The current Major Depressive Episode ( MDE ) confirm use Mini International Neuropsychiatric Interview ( MINI ) The patient MADRS total score ≥26 The patient CGIS score ≥4 The report duration current MDE ≥3 month . Other inclusion criterion may apply . The patient meet exclusion criterion list protocol , investigator 's opinion , unlikely comply protocol unsuitable reason .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>MDD</keyword>
</DOC>